Circulating miR-323-3p and miR-652: candidate markers for the presence and progression of acute coronary syndromes.

[1]  T. Rabelink,et al.  Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. , 2013, European heart journal.

[2]  M. Capogrossi,et al.  Diagnostic Potential of Plasmatic MicroRNA Signatures in Stable and Unstable Angina , 2013, PloS one.

[3]  T. Blondal,et al.  Assessing sample and miRNA profile quality in serum and plasma or other biofluids. , 2013, Methods.

[4]  M. Mayr,et al.  Prospective study on circulating MicroRNAs and risk of myocardial infarction. , 2012, Journal of the American College of Cardiology.

[5]  Alan S Maisel,et al.  Biomarkers in acute myocardial injury. , 2012, Translational research : the journal of laboratory and clinical medicine.

[6]  T. Luedde,et al.  Micro-RNA Profiling in Human Serum Reveals Compartment-Specific Roles of miR-571 and miR-652 in Liver Cirrhosis , 2012, PloS one.

[7]  A. Tijsen,et al.  Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? , 2012, Circulation research.

[8]  Donavan T. Cheng,et al.  Expression Profiling of Human Immune Cell Subsets Identifies miRNA-mRNA Regulatory Relationships Correlated with Cell Type Specific Expression , 2012, PloS one.

[9]  M. Zile,et al.  Relationship Between the Temporal Profile of Plasma microRNA and Left Ventricular Remodeling in Patients After Myocardial Infarction , 2011, Circulation. Cardiovascular genetics.

[10]  J. Bauersachs,et al.  Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. , 2011, Journal of molecular and cellular cardiology.

[11]  S. Fichtlscherer,et al.  Transcoronary Concentration Gradients of Circulating MicroRNAs , 2011, Circulation.

[12]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[13]  Toshihiro Tamura,et al.  Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage , 2011, Circulation. Cardiovascular genetics.

[14]  M. Soares,et al.  Identification of Differentially Expressed MicroRNAs in Osteosarcoma , 2011, Sarcoma.

[15]  H. Hwu,et al.  MicroRNA Expression Aberration as Potential Peripheral Blood Biomarkers for Schizophrenia , 2011, PloS one.

[16]  Jan A Staessen,et al.  Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease , 2010, Circulation. Cardiovascular genetics.

[17]  K. Yoshiura,et al.  Identification of pregnancy-associated microRNAs in maternal plasma. , 2010, Clinical chemistry.

[18]  Stefanie Dimmeler,et al.  Circulating MicroRNAs in Patients With Coronary Artery Disease , 2010, Circulation research.

[19]  Chunxiang Zhang,et al.  A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. , 2010, Clinical science.

[20]  Kunihiro Nishimura,et al.  Plasma microRNA 499 as a biomarker of acute myocardial infarction. , 2010, Clinical chemistry.

[21]  Federica Limana,et al.  Circulating microRNAs are new and sensitive biomarkers of myocardial infarction , 2010, European heart journal.

[22]  Yue Li,et al.  Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. , 2010, European heart journal.

[23]  Kang Li,et al.  Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. , 2010, Biochemical and biophysical research communications.

[24]  Frank Speleman,et al.  A novel and universal method for microRNA RT-qPCR data normalization , 2009, Genome Biology.

[25]  P. Libby,et al.  The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions , 2007, The Journal of experimental medicine.

[26]  Alan D. Lopez,et al.  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data , 2006, The Lancet.

[27]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[28]  Á. Avezum,et al.  A validated prediction model for all forms of acute coronary syndrome:estimating the risk of 6-month postdischarge death in an international registry , 2004 .

[29]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[30]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.

[31]  A. Richards,et al.  Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. , 1998, Clinical chemistry.

[32]  R. Doughty,et al.  Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairment , 1997, Clinical endocrinology.

[33]  A. Richards,et al.  Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. , 1993, The Journal of clinical endocrinology and metabolism.

[34]  J. Kato,et al.  Regional distribution of immunoreactive endothelin in porcine tissue: abundance in inner medulla of kidney. , 1989, Biochemical and biophysical research communications.

[35]  P. Brandt,et al.  Coronary arteriography; method of presentation of the arteriogram report and a scoring system. , 1977, Clinical radiology.